Merck reported mixed results with a decline in some sales areas and challenges like patent expirations, but showed strength in key growth sectors and a commitment to R&D and cost management. The narrowed earnings guidance and ongoing competitive pressures suggest a neutral short-term impact on the stock.

[0]